好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Alzheimer’s Disease Neuropathologic Change in Cognitively Impaired Prostate Cancer Survivors
Neuro-oncology
P1 - Poster Session 1 (11:45 AM-12:45 PM)
6-008
To determine if Alzheimer's disease neuropathic change (ADNC) is associated with androgen deprivation therapy (ADT) use in prostate cancer survivors with cognitive impairment.
ADT is an important treatment for the management of prostate cancer and has been associated with increased risk for cognitive impairment. The etiologic basis for ADT-related cognitive impairment is unknown.
We quantified ADNC (0-3; A: Thal amyloid phase, B: Braak neurofibrillary tangle stage, C: CERAD neuritc plaque score) in patients with pathologically confirmed diagnosis of prostate cancer from the Mayo Clinic Study of Aging. We collected details regarding oncologic care. We used t-test and Chi-square test to assess differences between continuous and categorical variables. We performed logistic regression corrected for age and APOE4-status to determine the association between ADT use and low (0-1)/high (2-3) ADNC.
Forty-six patients (mean 88 years at death, 48% APOE4 carriers) with history of prostate cancer (71 years at cancer diagnosis) and mild cognitive impairment or dementia with available neuropathology available were included. Thireteen (28%) patients received ADT (mean duration: 27 months). There were no demographic or other treatment differences by ADT status. However, patients who received ADT had higher PSA, Gleason score, more biochemical recurrences, and metastasis. Mean A (1.4 vs. 2.2, p=0.04), B (1.5 vs. 2.2, p=0.001), and C (1.3 vs. 2.2, p=0.007) scores were lower for patients who received ADT. Prior ADT use was associated with lower neurofibrillary tangle (OR: 0.08; 95% CI 0.01-0.43; p=0.0053) and neuritic plaque (OR: 0.09; 95% CI 0.03-0.46; p=0.0054) burden.
Amongst cognitively impaired prostate cancer survivors there is less ADNC in those who received ADT, suggesting that in these patients, cognitive impairment may be attributable to factors related to ADT in addition to ADNC. Future analyses will focus on determining other contributors to cognitive impairment in patients with prostate cancer.
Authors/Disclosures
Bryan J. Neth, MD, PhD (Mayo Clinic)
PRESENTER 		Dr. Neth has nothing to disclose.
Aivi Nguyen (Mayo Clinic) Aivi Nguyen has nothing to disclose.
Aditya Raghunathan, MD (Mayo Clinic) Dr. Raghunathan has nothing to disclose.
Eva Alden, PhD Dr. Alden has nothing to disclose.
Umar Ghaffar, MBBS Dr. Ghaffar has nothing to disclose.
Hugo Botha, MD (Mayo School of Graduate Medical 好色先生, Rochester) Dr. Botha has received research support from NIH. An immediate family member of Dr. Botha has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.
Vijay K. Ramanan, MD, PhD (Mayo Clinic) The institution of Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daridorexant trial for AD prevention (funded by Weston Family Foundation). The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. The institution of Dr. Ramanan has received research support from Roche/ADLM. The institution of Dr. Ramanan has received research support from American College of Radiology. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Speaker/CME Content with Clinical Care Options.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Kathryn J. Ruddy, MD The institution of Dr. Ruddy has received research support from National Institutes of Health. The institution of Dr. Ruddy has received research support from Department of Defense. Dr. Ruddy has received publishing royalties from a publication relating to health care.
Daniel S. Childs, MD Dr. Childs has nothing to disclose.
r. jeffrey karnes, MD The institution of Dr. karnes has received research support from FDA.
Jeffrey S Wefel Jeffrey S Wefel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas. Jeffrey S Wefel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Jeffrey S Wefel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intracellular Therapies. The institution of Jeffrey S Wefel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cogstate. The institution of Jeffrey S Wefel has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for GT Medical Technologies. The institution of Jeffrey S Wefel has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Novocure. Jeffrey S Wefel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with NCI.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .